On May 19, 2025, Qualigen Therapeutics, Inc. received a notification from Nasdaq regarding a deficiency for failing to timely file its quarterly report for the period ended March 31, 2025, which could lead to delisting. The company plans to address this issue at an upcoming hearing to regain compliance with Nasdaq's regulations.